Leslie Sloan - 23 Aug 2022 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (SYRE)

Reporting relationship: Chief Operating Officer
Issuer ticker: SYRE
Reported as of: 23 Aug 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 25 Aug 2022, 19:36:17 UTC
Prior SEC filing: 22 Feb 2022
Source filing: View source filing
Reporting owner signature: /s/ James Kastenmayer, by power of attorney

Key filing fact

Leslie Sloan filed Form 4 for Aeglea BioTherapeutics, Inc. (SYRE) on 25 Aug 2022.

Key facts

This page summarizes Leslie Sloan's Form 4 filing for Aeglea BioTherapeutics, Inc. (SYRE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 25 Aug 2022, 19:36.

Change

Previous filing in this sequence was filed on 22 Feb 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AGLE transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +130,000
Change %
Price: $0.000000
Shares after: 130,000
Date: 23 Aug 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 130,000
Exercise price: $0.6800
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option vests and becomes exercisable in 48 equal monthly installments beginning on September 23, 2022 until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors, the stock option will vest as to 80% of the award by January 1, 2023, and 1/48 of the stock option will vest and become exercisable monthly thereafter until such time as the option is 100% vested.